Avalo Therapeutics, Inc. - Class A Common Stock (AVTX)

37 filings reported holding AVTX - Avalo Therapeutics, Inc. - Class A Common Stock as of Q1 2025.
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 8,255,057 shares of 13,155,511 outstanding shares and own 63% of the company stock.
Largest 10 shareholders include BVF INC/IL (1,036,679 shares), ORBIMED ADVISORS LLC (967,000 shares), RA CAPITAL MANAGEMENT, L.P. (967,000 shares), Nantahala Capital Management, LLC (900,000 shares), Deep Track Capital, LP (859,876 shares), Affinity Asset Advisors, LLC (657,154 shares), PERCEPTIVE ADVISORS LLC (520,000 shares), TCG Crossover Management, LLC (483,000 shares), COMMODORE CAPITAL LP (483,000 shares), and RWA WEALTH PARTNERS, LLC (312,779 shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.